Becton, Dickinson and Company Q4: Shifting To High-Growth Areas
- Becton, Dickinson and Company is projected to achieve 8.8%-9.3% revenue growth in FY25, driven by new product launches and the APM business. The acquisition of Edwards Lifesciences' Critical Care product group is expected to significantly boost BD's Advanced Patient Monitoring segment. BD plans to reduce debt leverage to 2.5x and repurchase $1 billion in shares, enhancing financial stability and shareholder value.
- 11/12/2024
|
Becton Dickinson beats quarterly estimates on strength in drug-delivery devices
- Becton Dickinson surpassed analysts' expectations for fourth-quarter results on Thursday, helped by strong demand for its drug-delivery devices.
- 11/07/2024
|
Becton, Dickinson And HP Among 13 Companies To Announce Annual Dividend Increases In First Half Of November
- This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. I expect 13 companies to announce their annual increases in the first half of November, including double-digit increases from Automatic Data Processing, Roper Technologies, and Snap-on. Investors saw good 10%+ increases from insurer Brown & Brown, payment processor Visa, and specialty chemical company RPM in October.
- 11/03/2024
|
Why Matrix CIO is chasing Becton Dickinson and US Bancorp
- David Katz, chief investment officer at Matrix Asset Advisors, joins 'The Exchange' to discuss his picks in the markets, how to position for the future, and more.
- 09/24/2024
|
Becton, Dickinson and Company: Future Benefit From GLP-1 Drug Delivery
- I reiterate a 'Buy' rating for BDX with a fair value of $265 per share, driven by growth in GLP-1 drug delivery and the acquisition of Edwards Lifesciences' Critical Care. BDX's strong market position in prefilled syringes and self-administered injection systems positions it to benefit significantly from the fast-growing GLP-1 market, potentially adding $1 billion in revenue by 2030. The acquisition of Edwards Lifesciences' Critical Care product group for $4.2 billion is expected to accelerate BDX's revenue growth and expand margins, enhancing its smart connected care solutions.
- 09/13/2024
|
Becton, Dickinson And Company: Somewhat Undervalued, A Very Moderate Buy
- Becton, Dickinson is overwhelmingly considered undervalued by Wall Street analysts, with an average price target of ~$280 and highs of $312-$330. This is supported by my extensive DCF and comps models. BDX benefits from innovative products, strategic partnerships, and ongoing trends. The company boasts high margins and a reliable, growing dividend. However, the price is already pretty close to its all-time high and most price targets, so significant further appreciation is unlikely, making BDX a very moderate "Buy".
- 08/06/2024
|
Becton Dickinson tops profit estimates on demand for drug-delivery devices
- Becton Dickinson reported a better-than-expected third-quarter profit on Thursday, helped by strong demand for its drug-delivery devices.
- 08/01/2024
|
US FDA flags shortage of Becton Dickinson's blood test tubes
- The U.S. Food and Drug Administration issued an alert on Wednesday to laboratories and healthcare providers of a shortage of Becton Dickinson' blood test tubes used in diagnosing bacterial and fungal infections.
- 07/10/2024
|
Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash
- The buyer intends to fund deal with a combination of $1 billion in cash and $3.2 billion of new debt in a transaction that is one of its largest of many.
- 06/03/2024
|
Edwards Lifesciences to sell critical care products unit to Becton Dickinson for $4.2 bln
- Edwards Lifesciences on Monday said it has agreed to sell its Critical Care products unit to Becton Dickinson in an all-cash transaction valued at $4.2 billion.
- 06/03/2024
|
Edwards Lifesciences to sell its critical care product group for $4.2 billion to Becton Dickinson
- Shares of Edwards Lifesciences Corp. EW, -1.14% rallied 3% in premarket trading Monday, after the company announced an agreement to sell its critical care product group to Becton Dickinson & Co. BDX, +2.29% in a cash deal valued at $4.2 billion. Edwards said it plans to use the proceeds from the sale to fund investments for growth, such as in technologies for technologies for aortic, mitral, tricuspid and pulmonic patients, and in therapeutic areas for interventional heart failure.
- 06/03/2024
|
Becton, Dickinson And Polaris: The Market Is Dead Wrong About These Dividend Aristocrat Bargains
- Value investing may be out of favor due to the success of tech darlings like Nvidia and Amazon. However, value investing can still be done safely and responsibly, and generate exceptional returns, including 15% to 25% annual returns over several years. Dividend aristocrats like Becton, Dickinson and Polaris are trading at 52-week lows and present potentially attractive buying opportunities.
- 06/01/2024
|
Cramer's Mad Dash: Becton Dickinson and Co. and Owens & Minor
- CNBC's Jim Cramer delivers his daily Mad Dash.
- 05/14/2024
|
Becton Dickinson lifts profit view on strong surgical equipment demand
- Becton Dickinson raised its annual profit forecast and beat second-quarter profit estimates on Thursday, as the group banks on strong demand for its surgical equipment and syringes.
- 05/02/2024
|
Becton Dickinson to increase domestic production of syringes
- Becton Dickinson said on Thursday that it will increase domestic production of medical syringes.
- 03/21/2024
|
Becton, Dickinson And Company: Growth Starts To Normalize (Rating Upgrade)
- Becton, Dickinson and Company (BD) experienced weak growth in China, with a decline of 5.3% year-over-year. BD's major challenges, including the Alaris pump and Covid comparisons, are starting to normalize. The stock price is undervalued, leading to an upgrade in rating from 'Hold' to 'Buy' with a fair value of $250 per share.
- 03/04/2024
|
Becton Dickinson lifts 2024 profit forecast on surgical devices strength
- Becton Dickinson beat first-quarter profit estimates and raised its full-year earnings forecast on Thursday as it benefits from strong demand for its surgical equipment.
- 02/01/2024
|
Becton, Dickinson: 4 Reasons To Buy This Growth At A Reasonable Price Play
- Becton, Dickinson and Company has underperformed the market and healthcare sector in recent years. The company's balance sheet has improved significantly which I believe will allow for increased returns of capital to shareholders going forward. BDX's recent guidance for FY 2024 has lowered earnings expectations, but the company has a history of beating consensus estimates.
- 01/22/2024
|
Becton Dickinson CEO: Solutions that drive automation and efficiency are a big need in healthcare
- Becton Dickinson Chairman, President and CEO Tom Polen joins 'Mad Money' host Jim Cramer to talk inflation's impact on healthcare, the prefilled syringe market and more.
- 01/11/2024
|
There's a big focus on efficiency as hospitals feel inflationary pressures: Becton Dickinson CEO
- Becton Dickinson Chairman, President and CEO Tom Polen joins 'Mad Money' host Jim Cramer to talk inflation's impact on healthcare, the prefilled syringe market and more.
- 01/11/2024
|
Becton Dickinson CEO describes how new technology helps hospitals fight inflated operating costs
- In an interview with CNBC's Jim Cramer, Becton Dickinson CEO Tom Polen described how the medical device manufacturer's new technology can save hospitals money.
- 01/11/2024
|
US FDA clears Becton Dickinson's blood collection device
- Becton Dickinson said on Thursday the U.S. Food and Drug Administration (FDA) had cleared its less invasive blood collection device.
- 12/07/2023
|
Top 4 Health Care Stocks That Could Blast Off This Quarter - Acutus Medical (NASDAQ:AFIB), Becton Dickinson (NYSE:BDX)
- The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
- 11/17/2023
|
Following The Q4 Results, Becton, Dickinson and Company Is Still A Hold
- Becton, Dickinson, and Company is a healthcare company with strong fundamentals and a history of dividend growth. The company has shown robust execution of its 2025 strategy, positioning it for sustained growth and innovation in the medical technology space. However, there are risks to the investment, including slower EPS growth, competition, and a lack of margin of safety in the current valuation.
- 11/13/2023
|
Midday Movers: Disney Rises, Tesla and Becton Dickinson Fall
- U.S. equities fell midday ahead of comments from Fed Chair Jerome Powell that could offer clues about the future of monetary policy. The Dow, S&P 500, and Nasdaq were all lower.
- 11/09/2023
|
Becton, Dickinson And HP Among 13 Companies Announcing Annual Dividend Increases In The First Half Of November
- Visa and Exxon Mobil announced dividend increases in October, with Visa increasing its dividend by 15.6% and Exxon Mobil increasing its dividend by 4.4%. Several companies, including AbbVie, American Electric Power, and McDonalds, met or exceeded dividend increase predictions in October. Dividend growth slowed for companies like Amphenol, Black Hills, and Tompkins Financial due to various factors such as the current economic slowdown and flat or lower earnings.
- 10/30/2023
|
Becton, Dickinson Stock Is A Hold, Here's Why
- Becton, Dickinson and Company is a global healthcare company specializing in medical supplies, devices, and diagnostic products. BDX saw solid growth in Q3 driven by strong demand for pharmacy automation systems and medical devices. The company raised its revenue guidance for FY23 and expects continued profitability improvement in the near future.
- 10/04/2023
|
Becton Dickinson beats quarterly profit estimates on strong medical device sales
- Becton Dickinson beat Wall Street estimates for third-quarter profit on Thursday, helped by strong demand for its drug delivery devices and surgical equipment.
- 08/03/2023
|
Becton Dickinson Shares Jump After FDA Decision on Its Infusion System
- Shares of Becton Dickinson rose to their highest level since 2020 after the FDA gave 501(k) clearance to Becton Dickinson's updated BD Alaris Infusion System.
- 07/24/2023
|
Becton Dickinson shares hit record high after US FDA clears return of drug infusion system
- Shares of Becton Dickinson hit an all-time high on Monday and were last up 6.1% after the medical device maker received U.S. Food and Drug Administration clearance late on Friday for the market return of its drug infusion system.
- 07/24/2023
|
Why Shares of Becton, Dickinson Rose Monday
- The company filed a 501(k) resubmission for its new BD Alaris Infusion System two years ago. The company said it will begin immediately distributing the new Alaris Infusion System, and will remediate older versions of the device.
- 07/24/2023
|
Becton, Dickinson and Company: Still Not Very Healthy
- Becton, Dickinson and Company has seen another year of relative stagnation. Following the spinoff of the Diabetes Care unit, sales and earnings have taken a small setback. Valuations remain full at around 20 times adjusted earnings amidst some leverage still being apparent and with structural growth hard to come by.
- 06/20/2023
|
Becton, Dickinson: Business Should Beat H2 2023 Expectations
- I expect Becton, Dickinson and Company to beat 2H23 estimates due to reduced expectations and margin improvements. BDX's management has made progress in SKU rationalizations, workforce reduction, and enhancing the company's structural margin profile. The stable operating environment, procedure volume recovery, and hospital capital spending appetite support revenue growth for BDX.
- 06/08/2023
|
Becton Dickinson CEO: Q2 ‘was another quarter of exceeding expectations'
- Becton, Dickinson and Company CEO and President Tom Polen joins Yahoo Finance Live to discuss company earnings, growth opportunities in the home test kit market, biotech drugs, strong demand in the weight loss market, and the outlook for Becton Dickinson.
- 05/04/2023
|
Final Trades: GXO, Becton Dickinson, Freeport-McMoRan & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 01/09/2023
|
Is There More Room For Growth In Becton Dickinson Stock?
- Becton Dickinson stock (NYSE: BDX) has seen a 7% fall this year, faring better than the broader S&P500 index, down 17%.
- 11/23/2022
|
Becton Dickinson stock down 1.3% premarket as Q4 earnings beat tempered by soft fiscal 2023 guidance
- Becton Dickinson & Co. stock BDX, -0.55% slid 1.3% in premarket trade Thursday, after the medical tech and diagnostics company beat estimates for its fiscal fourth quarter but offered guidance that lagged. The Franklin Lakes, N.J.
- 11/10/2022
|
Becton Dickinson raises quarterly dividend by 4.6% to 91 cents a share
- Becton Dickinson & Co. BDX, -0.55% said Thursday its board has approved a 4.6% increase in its quarterly dividend to 91 cents a share. The medical tech and diagnostics company said the new dividend is payable Dec. 30 to shareholders of record as of Dec. 9.
- 11/10/2022
|
This Healthcare Company Is Likely To Offer Better Returns Over Eli Lilly Stock
- There is more to the comparison, and in the sections below, we discuss why we believe BDX stock will offer better returns than LLY stock in the next three years.
- 09/15/2022
|
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
- Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and strategic deals.
- 03/24/2022
|
Becton, Dickinson: Low Volatility Is A Strength In The Current Market
- Becton, Dickinson: Low Volatility Is A Strength In The Current Market
- 03/17/2022
|
Becton Dickinson (BDX) Crossed Above the 20-Day Moving Average: What That Means for Investors
- Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
- 02/24/2022
|
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
- Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.
- 02/23/2022
|
Becton Dickinson (BDX) Crossed Above the 20-Day Moving Average: What That Means for Investors
- Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
- 02/04/2022
|
Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q1 2022 Results - Earnings Call Transcript
- Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q1 2022 Results - Earnings Call Transcript
- 02/03/2022
|
Becton Dickinson Q1 Earnings Top Estimates, Raises FY22 Guidance On Higher COVID-19 Related Sales
- Becton Dickinson and Co BDX reported Q1 FY22 revenues of $4.9 billion, down 6% Y/Y (-5.9% on a currency-neutral basis), better than the consensus of $4.76 billion. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
- 02/03/2022
|
Becton Dickinson (BDX) Surpasses Q1 Earnings and Revenue Estimates
- Becton Dickinson (BDX) delivered earnings and revenue surprises of 27.27% and 4.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/03/2022
|
Should You Buy Becton, Dickinson and Company (BDX) Ahead of Earnings?
- Becton, Dickinson and Company (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/02/2022
|
Becton Dickinson Strengthens Post-Treatment Monitoring For Blood Cancers With Cytognos Acquisition
- Becton, Dickinson and Co (NYSE: BDX) has acquired Cytognos, a unit of Vitro SA, a Spanish diagnostics company that develops, produces, and sells fully integrated reagents, hardware, and software platforms. Deal terms were not disclosed.
- 02/01/2022
|
Becton Dickinson (BDX) Expected to Beat Earnings Estimates: Should You Buy?
- Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/27/2022
|
Why the Earnings Surprise Streak Could Continue for Becton Dickinson (BDX)
- Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/14/2022
|
Becton, Dickinson And Company: Stable, Profitable, And Offering At-Home COVID-19 Testing
- Beckton, Dickinson and Company is a Profitable Dividend Aristocrat that generates tons of cash.
- 01/12/2022
|
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
- Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic buyouts.
- 01/11/2022
|
BD (BDX) Partners With Retailers for At-Home COVID-19 Test
- BD (BDX) collaborates with retail partners and distributors to make the BD Veritor At-Home COVID-19 Test widely accessible.
- 12/27/2021
|
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
- Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.
- 12/08/2021
|
Becton Dickinson to name diabetes care spinoff 'embecta'
- Becton Dickinson & Co. BDX, +0.90% said Monday that the spinoff of its diabetes care business will be named "embecta." The previously announced spinoff, into an independent publicly traded company, is expected to be completed in the second quarter of 2022.
- 12/06/2021
|
Becton, Dickinson & Co. Is Trading at a Discount
- Shares of Becton, Dickinson and Co. ( BDX , Financial) reported earnings results earlier this month that came in above Wall Street analysts' estimates. Covid-19 remains a tailwind to the company's business, but the core segments also performed well.
- 11/29/2021
|
Rapid Covid-19 tests in high demand ahead of Thanksgiving
- CNBC's Meg Tirrell joins 'Squawk Box' to report on the increased demand for Covid-19 tests ahead of the Thanksgiving holiday.
- 11/23/2021
|
Becton, Dickinson Is A Strong Buy At $250
- Becton, Dickinson Is A Strong Buy At $250
- 11/18/2021
|
Qiagen, Becton Dickinson Settle Patent Infringement Lawsuit For $53M
- Qiagen N.V. (NYSE: QGEN) settled with Becton Dickinson & Co (NYSE: BDX) a patent infringement lawsuit related to Qiagen's NeuMoDx 96 and NeuMoDx 288 clinical PCR systems.
- 11/08/2021
|
Becton, Dickinson and Company's (BDX) CEO Tom Polen on Q4 2021 Results - Earnings Call Transcript
- Becton, Dickinson and Company's (BDX) CEO Tom Polen on Q4 2021 Results - Earnings Call Transcript
- 11/04/2021
|
Becton Dickinson (BDX) Q4 Earnings and Revenues Beat Estimates
- Becton Dickinson (BDX) delivered earnings and revenue surprises of 6.58% and 4.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/04/2021
|
Becton Dickinson Starts Selling New At-Home Rapid COVID-19 Tests
- Becton Dickinson and Co (NYSE: BDX) has partnered with Amazon.com Inc (NASDAQ: AMZN) to begin shipment of a new at-home rapid COVID-19 test that can confirm results using an entirely automated smartphone app. The BD Veritor At-Home COVID-19 Test, which U.S. regulators authorized in August, also automatically reports results to federal and state public health authorities.
- 10/26/2021
|
Can Becton Dickinson (BDX) Keep the Earnings Surprise Streak Alive?
- Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/26/2021
|
Bear Of The Day: Becton, Dickinson and Co (BDX)
- Despite a beating the number in the most recent report, this stock has fallen to the lowest Zacks Rank
- 10/05/2021
|
Becton Dickinson CEO on first Covid smartphone test and how it works
- Thomas Polen, Becton Dickenson CEO, joins Closing Bell to talk about his company's smartphone Covid test.
- 09/10/2021
|
Why Biden's Action Plan Is Bullish For COVID-19 Testing Stocks
- On Thursday, President Joe Biden revealed his new COVID-19 action plan, which includes $2 billion in government spending on 280 million rapid point of care and at-home COVID-19 tests. On Friday, Bank of America analyst Bob Hopkins said Biden's new plan is good news for test manufacturers, including Becton Dickinson and Co (NYSE:BDX) and Abbott Laboratories (NYSE:ABT).
- 09/10/2021
|
Becton, Dickinson And Company: One Of The Best Dividend SWANs You Can Buy Today
- Becton, Dickinson And Company: One Of The Best Dividend SWANs You Can Buy Today
- 09/10/2021
|
Notable Becton Dickinson Insider Trades $5.72 Million In Company Stock
- James Lim, Executive Vice President at Becton, Dickinson (NYSE:BDX), made a large buy and sell of company shares on September 3, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that James Lim purchased 14,584 Becton, Dickinson shares at a price of $134.73 per share for a total of $1,964,902 on September 3.
- 09/07/2021
|
BD (BDX) Veritor At-Home COVID-19 Test Receives EUA From FDA
- EUA for BD's (BDX) At-Home COVID-19 test is expected to boost home testing to prevent outbreaks and limit the rise in COVID-19 cases from the Delta variant.
- 08/26/2021
|
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
- Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and regulatory approvals.
- 08/26/2021
|
BD Locks FDA Emergency Use Nod For At-Home COVID-19 Antigen Test
- The FDA has issued an Emergency Use Authorization (EUA) for Becton Dickinson and Co's (NYSE: BDX) BD Veritor At-Home COVID-19 Test. Also Read: BD's Automated Molecular Diagnostics Platform Wins FDA Approval, Initial Test For HPV
- 08/26/2021
|
BD's Automated Molecular Diagnostics Platform Wins FDA Approval, Initial Test For HPV
- Becton Dickinson and Co (NYSE: BDX) has received FDA approval for its automated, sample-to-answer, high-throughput BD Cor system along with the BD Onclarity HPV Assay for extended genotyping of human papillomavirus (HPV). The modular and scalable BD Cor includes an automated sample preparation system, BD Cor PX, and an instrument that automates the BD Onclarity HPV assay, BD Cor GX.
- 08/25/2021
|
JPMorgan Downgrades Becton Dickinson On Muffled FY22 Outlook
- JPMorgan downgraded Becton Dickinson and Co (NYSE:BDX) to Neutral from Overweight with a price target of $265, down from $280. While Becton reported better than expected top and bottom-line Q3 results, analyst Robert Marcus tells investors that this was overshadowed by the company's "muted" Q4 and FY22 outlook.
- 08/06/2021
|
Becton Dickinson and Company (BDX) CEO Tom Polen on Q3 2021 Results - Earnings Call Transcript
- Becton Dickinson and Company (BDX) CEO Tom Polen on Q3 2021 Results - Earnings Call Transcript
- 08/05/2021
|
Becton Dickinson (BDX) Q3 Earnings and Revenues Surpass Estimates
- Becton Dickinson (BDX) delivered earnings and revenue surprises of 11.38% and 8.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/05/2021
|
Becton, Dickinson: Q3 Earnings Insights
- Shares of Becton, Dickinson (NYSE:BDX) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were up 24.55% year over year to $2.74, which beat the estimate of $2.44.
- 08/05/2021
|
BD's (BDX) Rapid COVID-19 Test for US Olympic Trial Swimmers
- BD (BDX) to provide rapid antigen testing for COVID-19 at the U.S. Olympic Team Trials and other competitive swimming events on behalf of USA Swimming.
- 06/16/2021
|
Matrix Asset's David Katz makes the case for Amgen, Viacom and Verizon
- David Katz, Matrix Asset Advisors chief investment officer, and Jerry Castellini, CastleArk Management chief investment officer, join 'The Exchange' to discuss their market outlook as the economy reopens and the names they think will have value in this market environment. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis.
- 05/27/2021
|
Becton Dickinson To Build Fourth Facility In Spain To Expand Pre-Filled Drug Delivery Business
- Becton Dickinson and Co (NYSE: BDX) will build a €165 million ($200 million) high-tech manufacturing facility in Zaragoza, Spain, that will create up to 600 jobs by 2030. BD plans to begin constructing the new plant in late 2021, and the new facility will be the fourth manufacturing plant for BD in Spain.
- 05/18/2021
|
Becton Dickinson To Spin Diabetes Care Unit In 2022
- , a leading global medical technology company, announced that its Board of Directors have unanimously authorized management to go ahead with a plan to spinoff the Diabetes Care business into an independent, publicly traded company (“NewCo”).
- 05/11/2021
|
Becton, Dickinson & Co. Continues to Shine
- Becton, Dickinson & Co. ( BDX , Financial) delivered another strong top and bottom-line beat when it reported earnings results last week.
- 05/11/2021
|
Syringe maker Becton, Dickinson CEO on the Covid supply chain
- CNBC's "Power Lunch" team discusses syringe supply and the Covid supply chain with Becton, Dickinson CEO Tom Polen.
- 05/06/2021
|
Becton, Dickinson and Company (BDX) CEO Tom Polen on Q2 2021 Results - Earnings Call Transcript
- Becton, Dickinson and Company (BDX) CEO Tom Polen on Q2 2021 Results - Earnings Call Transcript
- 05/06/2021
|
Becton Dickinson (BDX) Earnings Surpass Estimates in Q2
- Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal second quarter.
- 05/06/2021
|
Becton Dickinson To Spin-Off Diabetes Care Business: Highlights
- While reporting financial results for the second fiscal quarter of the year, during which revenues grew more than 15% to $4.9 billion, Becton Dickinson and Co (NYSE: BDX) also laid out its plans to spin off its diabetes-focused segment. Split Highlights: The split is expected to be completed in the first half of 2022, after which the segment will become a completely separate, publicly-traded company, tentatively dubbed “NewCo.”
- 05/06/2021
|
Becton Dickinson (BDX) Tops Q2 Earnings and Revenue Estimates
- Becton Dickinson (BDX) delivered earnings and revenue surprises of 4.93% and 1.47%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/06/2021
|
Becton Dickinson beats profit expectations, plans to spin off Diabetes Care business
- Becton Dickinson & Co. reported Thursday fiscal second-quarter profit and sales that rose above expectations, boosted by $480 million in COVID-19 testing sales, and announced plans to separate its Diabetes Care business into an independent publicly traded company. The medical technology company's stock was still inactive in premarket trading.
- 05/06/2021
|
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
- Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 04/19/2021
|
Becton, Dickinson - Three Reasons It Is A Buy
- Becton, Dickinson is a market leader in multiple medical supply, laboratory, and diagnostic product categories. The company has deleveraged after two major acquisitions and the leverage ratio is now near 2.5X.
- 04/19/2021
|
BD (BDX) Receives FDA EUA for Combination Rapid Antigen Test
- BD (BDX) gets FDA EUA for new rapid, antigen test, which can distinguish between COVID-19, influenza A and influenza B in a single test.
- 03/31/2021
|
BD gets FDA authorization for test that can detect COVID-19 and the flu
- Becton, Dickinson & Co. said it received emergency authorization from the Food and Drug Administration for a rapid, antigen test that can detect SARS-CoV-2 and two types of influenza. The test, which runs on the company's BD Veritor System, takes about 15 minutes to produce results and is expected to be available this summer.
- 03/30/2021
|
Becton, Dickinson And Company: Expect More Cash To Head To Shareholders
- Becton, Dickinson and Company is a Dividend Champion with 49 consecutive years of dividend. Shares currently yield 1.35%.
- 03/09/2021
|
Becton, Dickinson & Co.: Ride the Covid-19 Tailwinds
- Leading medical device manufacturer Becton, Dickinson & Co. (NYSE:BDX), or BD, recently reported earnings results that showed the company greatly benefited from Covid-19-related sales. BD provides the testing kits and vaccine injection devices being used to combat the virus.
- 02/25/2021
|
BD (BDX), Scanwell Health Collaborate on At-Home Coronavirus Test
- BD (BDX) plans to develop a lateral flow antigen test and pair it with the Scanwell Health mobile app via the latest partnership.
- 02/23/2021
|
BD (BDX) Gets EUA, CE Mark for New Molecular Diagnostic Test
- BD's (BDX) new test has the capability to detect SARS-CoV-2 and Influenza A+B in a single test.
- 02/16/2021
|
Becton Dickinson Lauded by Frost & Sullivan for Enhancing Patient Experience with Its BD Intevia™ Autoinjector
- The solution leverages a modular platform technology that allows rapid customization, optimizing time and cost for pharma companies SANTA CLARA, Calif., Feb. 16, 2021 /PRNewswire/ -- Based on its recent analysis of the global autoinjector drug delivery market, Frost & Sullivan recognizes...
- 02/16/2021
|
Becton, Dickinson's COVID-19/Influenza Combo Molecular Assay Wins FDA Emergency Use Nod
- The FDA has granted Emergency Use Authorization (EUA) to Becton Dickinson and Co's (NYSE: BDX) new molecular test for both SARS-CoV-2 and Influenza A+B. The new test has also received a CE mark in Europe.
- 02/12/2021
|
Becton Dickinson plans dual dollar/euro bond offerings to repay debt
- Medical technology company Becton Dickinson and Co. said Wednesday it is planning a dual-tranche bond offering in dollars and euros to raise the funds to repay outstanding debt. In a regulatory filing, Becton said it will offer $1 billion of 1.957% 10-year bonds and 600 million euros of 1.213% 15-year bonds.
- 02/10/2021
|
Covid-19 testing drives Becton Dickinson Q1 revenue growth
- Medical devices company Becton Dickinson beat the top and bottom line in its first-quarter results. Covid-19 testing helped drive its revenue growth to $867 million.
- 02/05/2021
|
Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q1 2021 Results - Earnings Call Transcript
- Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q1 2021 Results - Earnings Call Transcript
- 02/04/2021
|
Becton Dickinson (BDX) Earnings Surpass Estimates in Q1
- Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal first quarter.
- 02/04/2021
|
Becton Dickinson (BDX) Surpasses Q1 Earnings and Revenue Estimates
- Becton Dickinson (BDX) delivered earnings and revenue surprises of 44.90% and 0.13%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 02/04/2021
|
Becton Dickinson (BDX) Earnings Expected to Grow: What to Know Ahead of Q1 Release
- Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/28/2021
|
Becton, Dickinson's (BDX) Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Becton, Dickinson and Company (BDX).
- 01/21/2021
|
Final Trades: Zynga, Becton Dickinson & more
- The "Halftime Report" investment committee give their top picks to watch for the second half.
- 01/12/2021
|
Becton Dickinson stock rallies after upbeat revenue outlook
- Shares of Becton Dickinson & Co. rallied 2.3% in premarket trading Tuesday, after the medical technology company provided an upbeat outlook for its first quarter. For the quarter ended Dec. 31, the company expects to report revenue of $5.3 billion, up 26% from a year ago and above the FactSet consensus of $4.7 billion.
- 01/12/2021
|
Becton, Dickinson and Co.: A Fair Value Report
- Are investors getting a shot in the arm or backing into a needle?
- 01/03/2021
|
Becton, Dickinson & Co. Is a Highly Profitable, Recession-Proof Company
- The health care sector is considered a defensive sector as people will seek out treatment for illness and aliments regardless of the status of the economy. Many companies in this sector literally provide products that consumers cannot live without.
- 12/11/2020
|
Becton Dickinson Expects Covid Testing Sales to Hit $1.5 Billion
- When it comes to Covid-19, Becton, Dickinson and Co. (NYSE:BDX) hasn't gained the attention of vaccine developers like Pfizer Inc. (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ), nor those companies with treatments like Gilead Sciences Inc. (NASDAQ:GILD). But the New Jersey-based medical device company has hardly been sitting on the sidelines.
- 12/10/2020
|
Becton Dickinson to invest $1.2 billion to expand pre-fillable syringe manufacturing capacity for COVID vaccination
- Becton Dickinson & Co. said Wednesday it is planning to invest about $1.2 billion in pre-fillable syringe manufacturing capacity over the next four years. The Franklin Lakes, N.J.
- 12/02/2020
|
Minimal Dividend Growth Expected From Sysco And Becton Dickinson In Second Half Of November
- There were no big surprises in the dividend growth announcements in the first half of November. All the usual suspects offered up payout boosts. Long time dividend growth companies Emerson and Mercury General provided token increases of 1% to keep their dividend growth streaks going.
- 11/16/2020
|
Becton, Dickinson And Company: Reasonable Return Prospects, With Some Caveats
- Becton, Dickinson's reported non-GAAP earnings exclude a large amount of unusual items, some of which involve real monetary outlays. Over the last 3.75 years, dividends paid out of equity exceed the amount of income flowing into equity, if the excluded unusual items of expense are taken into account.
- 11/13/2020
|
Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q4 2020 Results - Earnings Call Transcript
- Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q4 2020 Results - Earnings Call Transcript
- 11/05/2020
|
Recap: Becton, Dickinson Q4 Earnings
- Shares of Becton, Dickinson (NYSE:BDX) were flat in pre-market trading after the company reported Q4 results.
- 11/05/2020
|
Were Hedge Funds Right About Becton, Dickinson and Company (BDX)?
- Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren't timid and registered double digit market beating gains. Financials, energy and industrial stocks aren't doing great but many of the stocks that delivered strong returns since March are still going very strong and hedge funds actually increased their positions in these stocks. In this article we will find out how hedge fund sentiment to Becton, Dickinson and Company (NYSE:BDX) changed recently.
- 10/26/2020
|
